NCT01688999: A trial that was reported late by National Cancer Institute (NCI)
This trial has reported, although it was 367 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT01688999 |
|---|---|
| Title | A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Sept. 11, 2012 |
| Completion date | Dec. 11, 2017 |
| Required reporting date | Dec. 11, 2018, midnight |
| Actual reporting date | Dec. 13, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 367 |